DANIEL HAMSTRA to Genetic Therapy
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Genetic Therapy.
Connection Strength
0.388
-
Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999 Aug 10; 10(12):1993-2003.
Score: 0.117
-
Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther. 1999 Jan 20; 10(2):235-48.
Score: 0.112
-
Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 2006 Jan; 13(2):127-37.
Score: 0.045
-
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther. 2004 Nov; 10(5):916-28.
Score: 0.042
-
Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy. Anticancer Res. 2004 May-Jun; 24(3a):1393-9.
Score: 0.041
-
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 2000 Jun; 7(12):1005-10.
Score: 0.031